CLL Market Update: Imbruvica Leads Way, Jump-Started By Robust Launch
Executive Summary
Recent BioMedTracker surveys suggest that most doctors are using new oral drugs – J&J/Pharmacyclics Imbruvica and Gilead’s Zydelig – generally in line with labeling, while uptake of Roche’s Rituxan-successor Gazyva is lower than expected.